Atria Wealth Solutions’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-32,313
Closed -$442K – 2006
2023
Q4
$442K Sell
32,313
-241
-0.7% -$2.96K 0.01% 1284
2023
Q3
$406K Sell
32,554
-448
-1% -$5.89K 0.01% 1236
2023
Q2
$447K Sell
33,002
-5,501
-14% -$75.9K 0.01% 1212
2023
Q1
$536K Sell
38,503
-648
-2% -$9.26K 0.01% 1091
2022
Q4
$556K Sell
39,151
-11,515
-23% -$167K 0.01% 1024
2022
Q3
$692K Buy
50,666
+8,776
+21% +$131K 0.01% 862
2022
Q2
$596K Buy
41,890
+1,865
+5% +$28.2K 0.01% 888
2022
Q1
$662K Buy
+40,025
New +$689K 0.01% 916

Other funds holding HQL

Atria Wealth Solutions's HQL Position: Q1 2024 in Review

Atria Wealth Solutions sold out of abrdn Life Sciences Investors (HQL) in Q1 2024, closing a stake of 32,313 shares — an estimated $442K sold.

Atria Wealth Solutions first reported a position in HQL in Q1 2022 and held it in 8 quarters. The position peaked at $692K in Q3 2022. 79 funds tracked by Wall St. Rank hold HQL as of Q1 2024.

  • Atria Wealth Solutions reported no remaining abrdn Life Sciences Investors position as of Q1 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 32,313 abrdn Life Sciences Investors shares in Q1 2024, an estimated $442K.
  • Atria Wealth Solutions first reported a position in abrdn Life Sciences Investors in Q1 2022 and held it in 8 quarters.
  • Atria Wealth Solutions's abrdn Life Sciences Investors position peaked at $692K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2024.

Based on Atria Wealth Solutions's 13F filing for Q1 2024, filed 13 May 2024.